您的购物车当前为空
别名 SMT19969
Ridinilazole (SMT19969) 是一种新型的窄谱非吸收性抗生素。它显示出对艰难梭菌的有效抑制作用 (MIC90=0.125 mg/L),并且比甲硝唑 (MIC90 = 8 mg/L) 或万古霉素 (MIC90 = 2 mg/L) 更有效。


为众多的药物研发团队赋能,
让新药发现更简单!
Ridinilazole (SMT19969) 是一种新型的窄谱非吸收性抗生素。它显示出对艰难梭菌的有效抑制作用 (MIC90=0.125 mg/L),并且比甲硝唑 (MIC90 = 8 mg/L) 或万古霉素 (MIC90 = 2 mg/L) 更有效。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 412 | In Stock | |
| 5 mg | ¥ 822 | In Stock | |
| 10 mg | ¥ 1,390 | In Stock | |
| 25 mg | ¥ 2,470 | In Stock | |
| 50 mg | ¥ 3,370 | In Stock | |
| 100 mg | ¥ 4,570 | In Stock | |
| 200 mg | ¥ 6,170 | In Stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 852 | In Stock |
Ridinilazole 相关产品
| 产品描述 | Ridinilazole (SMT19969) is a novel narrow-spectrum nonabsorbable antibiotic. Ridinilazole showed potent inhibition of C. difficile (MIC90=0.125 mg/L) and was markedly more active than either metronidazole (MIC90 = 8 mg/L) or vancomycin (MIC90 = 2 mg/L). |
| 靶点活性 | C. difficile:8 µg/mL (MIC90) |
| 体内活性 | Ridinilazole是一种正在研发中的新型抗菌化合物,用于治疗CDI。由于其高度针对性的活性谱和对正常肠道菌群的保护作用,Ridinilazole相较于CDI的主要抗生素治疗化合物metronidazole和vancomycin,具有显著优势。Ridinilazole对C. difficile具有杀菌作用,并展现出延长的抗菌后效应。此外,使用Ridinilazole治疗能够减少毒素产生。 |
| 别名 | SMT19969 |
| 分子量 | 388.42 |
| 分子式 | C24H16N6 |
| CAS No. | 308362-25-6 |
| Smiles | c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1 |
| 密度 | 1.372 g/cm3 (Predicted) |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 55 mg/mL (141.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容